The Impact of Glycosylation on the Pharmacokinetics of a TNFR2:Fc Fusion Protein Expressed in Glycoengineered Pichia Pastoris

[1]  D. Driver,et al.  FcRn Affinity-Pharmacokinetic Relationship of Five Human IgG4 Antibodies Engineered for Improved In Vitro FcRn Binding Properties in Cynomolgus Monkeys , 2012, Drug Metabolism and Disposition.

[2]  S. Hamilton,et al.  Elimination of β-mannose glycan structures in Pichia pastoris. , 2011, Glycobiology.

[3]  R. Kontermann,et al.  Strategies for extended serum half-life of protein therapeutics. , 2011, Current opinion in biotechnology.

[4]  Janice M Reichert,et al.  Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies , 2011, mAbs.

[5]  B. Carr,et al.  Monoclonal Antibodies with Identical Fc Sequences Can Bind to FcRn Differentially with Pharmacokinetic Consequences , 2011, Drug Metabolism and Disposition.

[6]  J. Isaacs,et al.  Anti-TNF therapy. , 2011, Best practice & research. Clinical rheumatology.

[7]  J. Hochman,et al.  Pharmacokinetics of IgG1 monoclonal antibodies produced in humanized Pichia pastoris with specific glycoforms: a comparative study with CHO produced materials. , 2011, Biologicals : journal of the International Association of Biological Standardization.

[8]  Yow-Ming C Wang,et al.  Investigation of the Pharmacokinetics of Romiplostim in Rodents with a Focus on the Clearance Mechanism , 2011, Pharmaceutical Research.

[9]  Gary Walsh,et al.  Biopharmaceutical benchmarks 2010 , 2010, Nature Biotechnology.

[10]  C. Ware,et al.  Tumor Necrosis Factor and Anti-Tumor Necrosis Factor Therapies , 2010, The Journal of Rheumatology. Supplement.

[11]  Pamela J. Björkman,et al.  An intracellular traffic jam: Fc receptor-mediated transport of immunoglobulin G. , 2010, Current opinion in structural biology.

[12]  Tetsu Kobayashi,et al.  Importance of Neonatal FcR in Regulating the Serum Half-Life of Therapeutic Proteins Containing the Fc Domain of Human IgG1: A Comparative Study of the Affinity of Monoclonal Antibodies and Fc-Fusion Proteins to Human Neonatal FcR , 2010, The Journal of Immunology.

[13]  I. Sandlie,et al.  Cross-species Binding Analyses of Mouse and Human Neonatal Fc Receptor Show Dramatic Differences in Immunoglobulin G and Albumin Binding* , 2009, The Journal of Biological Chemistry.

[14]  D. Danilenko,et al.  Evidence for an Asialoglycoprotein Receptor on Nonparenchymal Cells for O-Linked Glycoproteins , 2008, Journal of Pharmacology and Experimental Therapeutics.

[15]  T. Gerngross,et al.  Use of high-performance anion exchange chromatography with pulsed amperometric detection for O-glycan determination in yeast , 2008, Nature Protocols.

[16]  A. Datta-Mannan,et al.  Humanized IgG1 Variants with Differential Binding Properties to the Neonatal Fc Receptor: Relationship to Pharmacokinetics in Mice and Primates , 2007, Drug Metabolism and Disposition.

[17]  Jack Hoopes,et al.  Humanization of Yeast to Produce Complex Terminally Sialylated Glycoproteins , 2006, Science.

[18]  Teresa Mitchell,et al.  Engineering of an artificial glycosylation pathway blocked in core oligosaccharide assembly in the yeast Pichia pastoris: production of complex humanized glycoproteins with terminal galactose. , 2004, Glycobiology.

[19]  Byung-Kwon Choi,et al.  Use of combinatorial genetic libraries to humanize N-linked glycosylation in the yeast Pichia pastoris , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Ana Conesa,et al.  Filamentous fungi as cell factories for heterologous protein production. , 2002, Trends in biotechnology.

[21]  R. Ober,et al.  Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. , 2001, International immunology.

[22]  J. Egrie,et al.  Development and characterization of novel erythropoiesis stimulating protein (NESP) , 2001, British Journal of Cancer.

[23]  P. Stahl,et al.  The mannose receptor is a pattern recognition receptor involved in host defense. , 1998, Current opinion in immunology.

[24]  P. Bjorkman,et al.  High-affinity binding of the neonatal Fc receptor to its IgG ligand requires receptor immobilization. , 1997, Biochemistry.

[25]  M. Rogge,et al.  Immunomodulation by LFA3TIP, an LFA-3/IgG1 fusion protein: cell line dependent glycosylation effects on pharmacokinetics and pharmacodynamic markers. , 1995, Therapeutic immunology.

[26]  C A Smith,et al.  Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. , 1993, Journal of immunology.

[27]  D. Goeddel,et al.  Biochemical characterization of the extracellular domain of the 75-kilodalton tumor necrosis factor receptor. , 1993, Biochemistry.

[28]  E. Goldwasser,et al.  On the mechanism of erythropoietin-induced differentiation. 13. The role of sialic acid in erythropoietin action. , 1974, The Journal of biological chemistry.

[29]  R. H. Painter,et al.  Studies on the role of sialic acid in the physical and biological properties of erythropoietin. , 1972, Canadian journal of biochemistry.

[30]  E. Goldwasser,et al.  On the mechanism of erythropoietin-induced differentiation , 1965 .

[31]  H. Borsook,et al.  Inactivation of Erythropoietin by Neuraminidase and by Mild Substitution Reactions , 1960, Nature.

[32]  Teresa Mitchell,et al.  Production of complex human glycoproteins in yeast. , 2003, Science.

[33]  A. Schwartz.  Trafficking of asialoglycoproteins and the asialoglycoprotein receptor. , 1991, Targeted diagnosis and therapy.